Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Senseonics Holdings, Inc. specializes in the development of continuous glucose monitoring (CGM) systems for diabetes management, particularly its Eversense product, which features an implantable sensor designed for long-term use. The company's competitive position is bolstered by its unique technology that allows for a 90-day sensor life, significantly longer than traditional CGM systems, which typically require more frequent replacements.
Senseonics generates revenue primarily through the sale of its Eversense CGM systems, which are priced at a premium due to their innovative technology and extended sensor life. The company benefits from a growing diabetic population and increasing demand for advanced diabetes management solutions, providing it with pricing power in a niche market.
Regulatory approvals for new products or indications, particularly in the US and EU markets
Partnerships with healthcare providers and payers to expand market access
Sales growth in the diabetes management segment, particularly in the CGM market
Technological advancements or enhancements to the Eversense system
Technological disruption from competitors developing superior CGM technologies
Regulatory changes that could impact product approvals or reimbursement policies
Intense competition from established players like Dexcom and Abbott in the CGM market
Emerging entrants that may offer lower-cost alternatives
High debt levels relative to equity, which could constrain operational flexibility
Negative cash flow impacting liquidity and funding for growth initiatives
moderate - The demand for diabetes management products is somewhat insulated from economic cycles, but overall healthcare spending can be affected by economic downturns.
Interest rates can impact the company's financing costs, particularly as it may seek additional capital for R&D and expansion. Higher rates could also affect consumer spending on healthcare products.
minimal - The company is not heavily reliant on credit markets for its operations, although access to capital markets could be important for growth initiatives.
growth - Investors are likely attracted to the potential for rapid revenue growth in the expanding diabetes management market.
high - The stock has exhibited significant volatility, reflecting both operational challenges and market sentiment.
